以糖蛋白类肿瘤标志物为靶向的嵌合抗原受体 修饰T细胞研究进展
| 作者: |
1莫然,
1王东进
1 南京大学医学院附属鼓楼医院心胸外科，南京 210008 |
| 通讯: |
王东进
Email: gldjw@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2015.01.030 |
摘要
嵌合抗原受体(chimeric antigen receptor，CAR)修饰T细胞是目前肿瘤治疗中新的靶向疗法，通过 单链抗体(single chain fragment variable，scFv)-共刺激分子-T细胞信号转导区构成的嵌合模式修饰T 细胞，赋予T细胞非MHC依赖性靶向杀伤肿瘤细胞的能力，在动物模型及临床试验中取得了良好 的效果。糖蛋白类肿瘤标志物由于其良好的靶向性成为了CAR修饰T细胞新的靶点，针对糖蛋白类 肿瘤标志物的靶向研究显示出良好的临床前景，但是也要考虑到脱靶效应，转染方式等问题对该 治疗在临床运用的限制。相信随着研究的逐渐深入，基于CAR修饰T细胞的糖蛋白类肿瘤标志物靶 向治疗会取得更大的突破。
关键词：
嵌合抗原受体
糖蛋白类肿瘤标志物
基因治疗
靶向治疗
Research progress in chimeric antigen receptor modified T cells targeted glycoprotein tumor marker
CorrespondingAuthor: WANG Dongjin Email: gldjw@163.com
DOI: 10.3978/j.issn.2095-6959.2015.01.030
Abstract
Chimeric antigen receptor (CAR) modified T cells is an emerging targeted therapy, CAR is consisted of single chain fragment variable (scFv), costimulatory molecules and T cells signal transduction domain, which could make T cells non-MHC-restricted targeting kill tumor cells. Experiments of CAR modified T cells in both animal models and clinical practice have got satisfied results. Glycoprotein tumor markers are promising targets of CAR modified T cells because of their favorable targeting. Targeted therapy researches aim at glycoprotein tumor marker revealed bright prospects in clinical applications. Nevertheless, some questions like off-target effect and disputed transfection ways should be considered as potential restricted factors in clinical application. We believe CAR modified T cells therapy targeted glycoprotein tumor marker could get more breakthroughs with in-depth researches.